We welcome those interested in NIDA’s HIV research. Watch this space for messages from the ARP scientific leadership team on interesting new findings in the field as well as funding opportunities from NIDA.
November 2020
-
We are pleased to highlight two new NIDA/NIMHD co-funded opportunities:
-
First - we are seeking innovative projects that directly engage at risk populations, including structural interventions that can improve access to substance use prevention, treatment and harm reduction initiatives. We are especially interested in interventions that will include collaborations with diverse local stakeholders and address comorbidities such as intimate partner violence, marginal housing or serious mental disorders. See Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection
-
We are also seeking cost-effective care innovations for people who are HIV positive or suffer from substance use disorders, with a focus on harm reduction service settings in multiple geographic hotspots. Interventions could highlight novel approaches to PrEP delivery and/or clinic-level culturally competent components to reduce health care related stigma with a focus on racial/ethnic minorities, and/or sexual and gender minorities. See Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care.
-
-
Take note of the new NIH Stephen I. Katz Early Stage Investigator Research Project Grant funding opportunities, which support innovative projects that represent a change in research direction for early stage investigators.
- Congratulations to the HTPN 084 study scientific team for their new findings that demonstrate the superiority of long-acting injectable Cabotegravir to daily oral FTC/TDF for HIV prevention among certain populations of women. This remarkable advance signals an area of important research for us to answer questions about the acceptability, feasibility, and implementation of this potential tool into the care of women who use drugs.